CY1124749T1 - Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων - Google Patents
Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματωνInfo
- Publication number
- CY1124749T1 CY1124749T1 CY20211101015T CY211101015T CY1124749T1 CY 1124749 T1 CY1124749 T1 CY 1124749T1 CY 20211101015 T CY20211101015 T CY 20211101015T CY 211101015 T CY211101015 T CY 211101015T CY 1124749 T1 CY1124749 T1 CY 1124749T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- dipyrazole
- autoimmune diseases
- derivatives useful
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) όπου οι ομάδες R1, Cy και Υ ορίζονται στο παρόν, οι οποίες είναι κατάλληλες για την θεραπεία νοσημάτων που σχετίζονται με την ΒΤΚ, και διαδικασίες για την παραγωγή των ενώσεων αυτών, φαρμακευτικά σκευάσματα, τα οποία περιέχουν τις ενώσεις αυτές και τις μεθόδους χρήσης τους.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268278P | 2015-12-16 | 2015-12-16 | |
| US201662431008P | 2016-12-07 | 2016-12-07 | |
| PCT/US2016/066799 WO2017106429A2 (en) | 2015-12-16 | 2016-12-15 | Heteroaromatic compounds as btk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124749T1 true CY1124749T1 (el) | 2022-07-22 |
Family
ID=58737849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101015T CY1124749T1 (el) | 2015-12-16 | 2021-11-24 | Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9975882B2 (el) |
| EP (1) | EP3390390B1 (el) |
| JP (1) | JP6976947B2 (el) |
| KR (1) | KR20180095655A (el) |
| CN (1) | CN108368086B (el) |
| AU (1) | AU2016370743B2 (el) |
| BR (1) | BR112018011969B1 (el) |
| CA (1) | CA3005268C (el) |
| CL (1) | CL2018001569A1 (el) |
| CO (1) | CO2018005954A2 (el) |
| CY (1) | CY1124749T1 (el) |
| DK (1) | DK3390390T3 (el) |
| EA (1) | EA034561B1 (el) |
| ES (1) | ES2897910T3 (el) |
| HK (1) | HK1256795A1 (el) |
| HR (1) | HRP20211845T1 (el) |
| HU (1) | HUE056877T2 (el) |
| IL (1) | IL259281B (el) |
| LT (1) | LT3390390T (el) |
| MX (1) | MX2018007333A (el) |
| MY (1) | MY197440A (el) |
| PE (1) | PE20181074A1 (el) |
| PH (1) | PH12018501248A1 (el) |
| PL (1) | PL3390390T3 (el) |
| PT (1) | PT3390390T (el) |
| RS (1) | RS62525B1 (el) |
| SA (1) | SA518391864B1 (el) |
| SG (1) | SG11201804890TA (el) |
| SI (1) | SI3390390T1 (el) |
| TW (1) | TWI726017B (el) |
| WO (1) | WO2017106429A2 (el) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP201706748B (en) | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| KR20180095655A (ko) * | 2015-12-16 | 2018-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 자가 면역 질환의 치료에 유용한 비피라졸릴 유도체 |
| MA49809A1 (fr) | 2015-12-16 | 2021-08-31 | Loxo Oncology Inc | Composés utilisés comme inhibiteurs de kinase |
| JP6916185B2 (ja) | 2016-01-13 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのイソキノロン類 |
| WO2019027860A1 (en) * | 2017-08-01 | 2019-02-07 | Boehringer Ingelheim International Gmbh | INTERMEDIATE COMPOUNDS AND METHODS |
| CA3224945A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| US20220175772A1 (en) * | 2019-05-23 | 2022-06-09 | Novartis Ag | Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
| WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2001056993A2 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| PL210475B1 (pl) | 2001-08-13 | 2012-01-31 | Janssen Pharmaceutica Nv | Pochodna 2,4,5-tripodstawionego tiazolilu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
| US7307097B2 (en) | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
| FR2881426B1 (fr) | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
| WO2007117692A2 (en) | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
| LT2530083T (lt) | 2006-09-22 | 2016-09-26 | Pharmacyclics Llc | Brutono tirozinkinazės inhibitoriai |
| EP2561875A3 (en) | 2007-03-28 | 2013-06-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| PL2310528T3 (pl) | 2008-07-29 | 2014-04-30 | Univ Liege | Marker genetyczny do testowania brachyspiny i płodności u bydła |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| BR112012014884A2 (pt) | 2009-12-17 | 2016-03-22 | Merck Patent Gmbh | inibidores de esfingosina quinase |
| SG185617A1 (en) | 2010-05-31 | 2012-12-28 | Ono Pharmaceutical Co | Purinone derivative |
| WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
| GEP201706748B (en) * | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2014068527A1 (en) | 2012-11-02 | 2014-05-08 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| WO2014151620A1 (en) * | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
| WO2015116485A1 (en) * | 2014-01-29 | 2015-08-06 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as btk inhibitors |
| KR20180095655A (ko) * | 2015-12-16 | 2018-08-27 | 베링거 인겔하임 인터내셔날 게엠베하 | 자가 면역 질환의 치료에 유용한 비피라졸릴 유도체 |
-
2016
- 2016-12-15 KR KR1020187020450A patent/KR20180095655A/ko active IP Right Grant
- 2016-12-15 RS RS20211356A patent/RS62525B1/sr unknown
- 2016-12-15 HU HUE16867378A patent/HUE056877T2/hu unknown
- 2016-12-15 MY MYPI2018000892A patent/MY197440A/en unknown
- 2016-12-15 TW TW105141510A patent/TWI726017B/zh active
- 2016-12-15 WO PCT/US2016/066799 patent/WO2017106429A2/en active Application Filing
- 2016-12-15 BR BR112018011969-5A patent/BR112018011969B1/pt active IP Right Grant
- 2016-12-15 EA EA201891399A patent/EA034561B1/ru not_active IP Right Cessation
- 2016-12-15 MX MX2018007333A patent/MX2018007333A/es active IP Right Grant
- 2016-12-15 PE PE2018001111A patent/PE20181074A1/es unknown
- 2016-12-15 US US15/379,745 patent/US9975882B2/en active Active
- 2016-12-15 CN CN201680072250.3A patent/CN108368086B/zh active Active
- 2016-12-15 SG SG11201804890TA patent/SG11201804890TA/en unknown
- 2016-12-15 HR HRP20211845TT patent/HRP20211845T1/hr unknown
- 2016-12-15 JP JP2018531127A patent/JP6976947B2/ja active Active
- 2016-12-15 PL PL16867378T patent/PL3390390T3/pl unknown
- 2016-12-15 LT LTEPPCT/US2016/066799T patent/LT3390390T/lt unknown
- 2016-12-15 PT PT168673788T patent/PT3390390T/pt unknown
- 2016-12-15 CA CA3005268A patent/CA3005268C/en active Active
- 2016-12-15 AU AU2016370743A patent/AU2016370743B2/en active Active
- 2016-12-15 ES ES16867378T patent/ES2897910T3/es active Active
- 2016-12-15 EP EP16867378.8A patent/EP3390390B1/en active Active
- 2016-12-15 DK DK16867378.8T patent/DK3390390T3/da active
- 2016-12-15 SI SI201631382T patent/SI3390390T1/sl unknown
-
2017
- 2017-10-12 US US15/782,214 patent/US20180030037A1/en not_active Abandoned
-
2018
- 2018-04-09 US US15/947,978 patent/US20180222893A1/en not_active Abandoned
- 2018-05-10 IL IL259281A patent/IL259281B/en active IP Right Grant
- 2018-06-12 CO CONC2018/0005954A patent/CO2018005954A2/es unknown
- 2018-06-13 PH PH12018501248A patent/PH12018501248A1/en unknown
- 2018-06-13 CL CL2018001569A patent/CL2018001569A1/es unknown
- 2018-06-23 SA SA518391864A patent/SA518391864B1/ar unknown
- 2018-09-21 US US16/137,790 patent/US20190092759A1/en not_active Abandoned
- 2018-12-11 HK HK18115878.5A patent/HK1256795A1/zh unknown
-
2019
- 2019-08-29 US US16/555,205 patent/US20200055843A1/en not_active Abandoned
-
2020
- 2020-07-23 US US16/936,821 patent/US20210009567A1/en not_active Abandoned
-
2021
- 2021-11-24 CY CY20211101015T patent/CY1124749T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124749T1 (el) | Παραγωγα διπυραζολιου χρησιμα για την θεραπεια αυτοανοσων νοσηματων | |
| CY1123598T1 (el) | Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες | |
| CY1121571T1 (el) | Ανοσορρυθμιστες | |
| CY1122012T1 (el) | Ενωσεις ως ρυθμιστες του ror γαμμα | |
| MD3582853T2 (ro) | Compuși di-nucleotidici ciclici pentru tratamentul cancerului | |
| CY1123417T1 (el) | Παραγωγα τετρα�δροϊσοκινολινης | |
| CY1120893T1 (el) | Μεθοδοι για αγωγη μολυνσεων ιου filoviridae | |
| CY1121706T1 (el) | Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης | |
| CY1124638T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων | |
| CY1122534T1 (el) | Νεες ενωσεις μεθυλο-πιπεριδινης χρησιμες για την αναστολη της μ1κροσωμικης συνθετασης-1 της προσταγλανδινης ε2 | |
| CY1122415T1 (el) | Κυκλοπροπυλαμινες ως lsd1 αναστολεις | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1122803T1 (el) | Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων | |
| CY1123581T1 (el) | Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων | |
| CY1120029T1 (el) | Παραγωγα 6-(5-υδροξυ-1η-πυραζολ-1-υλ) νικοτιναμιδιου και χρηση τους ως αναστολεις phd | |
| CY1122613T1 (el) | Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139 | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1120991T1 (el) | Νεα παραγωγα αμινοξεος, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
| BR112017012859A2 (pt) | fosforamidatos para o tratamento do vírus da hepatite b | |
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| CY1120864T1 (el) | Ενωσεις πυραζολης και η χρηση τους ως αναστολεις διαυλων ασβεστιου τυπου τ | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| CY1120420T1 (el) | Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης |